🎉 M&A multiples are live!
Check it out!

Seres Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Seres Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Seres Therapeutics Overview

About Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.


Founded

2010

HQ

United States of America
Employees

233

Financials

LTM Revenue $4.2M

LTM EBITDA -$109M

EV

$176M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Seres Therapeutics Financials

Seres Therapeutics has a last 12-month revenue of $4.2M and a last 12-month EBITDA of -$109M.

In the most recent fiscal year, Seres Therapeutics achieved revenue of n/a and an EBITDA of -$120M.

Seres Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Seres Therapeutics valuation multiples based on analyst estimates

Seres Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $126M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$94.3M -$120M XXX XXX XXX
EBITDA Margin -75% -Infinity% XXX XXX XXX
Net Profit -$250M -$114M XXX XXX XXX
Net Margin -198% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Seres Therapeutics Stock Performance

As of April 15, 2025, Seres Therapeutics's stock price is $1.

Seres Therapeutics has current market cap of $116M, and EV of $176M.

See Seres Therapeutics trading valuation data

Seres Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$176M $116M XXX XXX XXX XXX $-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Seres Therapeutics Valuation Multiples

As of April 15, 2025, Seres Therapeutics has market cap of $116M and EV of $176M.

Seres Therapeutics's trades at 41.7x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.

Analysts estimate Seres Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Seres Therapeutics and 10K+ public comps

Seres Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $176M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.5x XXX XXX XXX
P/E 850.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Seres Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Seres Therapeutics Valuation Multiples

Seres Therapeutics's NTM/LTM revenue growth is 148%

Seres Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Seres Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Seres Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Seres Therapeutics and other 10K+ public comps

Seres Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 28% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Seres Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Seres Therapeutics M&A and Investment Activity

Seres Therapeutics acquired  XXX companies to date.

Last acquisition by Seres Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Seres Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Seres Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Seres Therapeutics

When was Seres Therapeutics founded? Seres Therapeutics was founded in 2010.
Where is Seres Therapeutics headquartered? Seres Therapeutics is headquartered in United States of America.
How many employees does Seres Therapeutics have? As of today, Seres Therapeutics has 233 employees.
Who is the CEO of Seres Therapeutics? Seres Therapeutics's CEO is Mr. Eric D. Shaff.
Is Seres Therapeutics publicy listed? Yes, Seres Therapeutics is a public company listed on NAS.
What is the stock symbol of Seres Therapeutics? Seres Therapeutics trades under MCRB ticker.
When did Seres Therapeutics go public? Seres Therapeutics went public in 2015.
Who are competitors of Seres Therapeutics? Similar companies to Seres Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Seres Therapeutics? Seres Therapeutics's current market cap is $116M
What is the current revenue of Seres Therapeutics? Seres Therapeutics's last 12-month revenue is $4.2M.
What is the current EBITDA of Seres Therapeutics? Seres Therapeutics's last 12-month EBITDA is -$109M.
What is the current EV/Revenue multiple of Seres Therapeutics? Current revenue multiple of Seres Therapeutics is 41.7x.
What is the current EV/EBITDA multiple of Seres Therapeutics? Current EBITDA multiple of Seres Therapeutics is -1.6x.
Is Seres Therapeutics profitable? Yes, Seres Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.